Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P050047/S098

Ultra, Ultra XC, Ultra Plus XC

Allergan · Decision date Aug 11, 2026

FDA DECISIONP050047/S098

What did the FDA approve?

FDA records P050047/S098 as a supplement to PMA P050047, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 11, 2026.

FDA approval order statement

Approval for using the sodium hyaluronate manufactured from HTLs additional manufacturing line (HTL4) as raw materials for Juvéderm products.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
General, Plastic Surgery
Decision date
Aug 11, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P050047/S098
Regulatory pathway
PMA supplement
Applicant
Allergan
Product code
LMH
Decision code
APPR
Decision date
Aug 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Allergan
Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P050047. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P050047 · Original PMA

    JUVEDERM 24HV, JUVEDERM 30 AND JUVEDERM 30HV GEL IMPLANTS

  2. P050047/S098 received

    Application receipt date recorded by FDA.

  3. P050047/S105 · Related supplement

    Juvéderm Ultra XC, and Juvéderm Ultra Plus XC (hereafter referred to as Ultra XC and Ultra Plus XC)

  4. P050047/S098 · FDA decision

    Normal 180 Day Track

  5. P050047/S107 · Related supplement

    Juvéderm Ultra XC, and Juvéderm Ultra Plus XC

  6. P050047/S106 · Related supplement

    Juvéderm Ultra XC; Juvéderm Ultra Plus XC

Timeline entries are records held by MedtechLedger for P050047. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050047

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA approvalJun 2, 2006FDA
AllerganPMA supplementAug 14, 2025FDA
AllerganPMA supplementAug 28, 2026FDA
AllerganPMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA
saypha ChiQP250021/S001
Croma-Pharma GmbHPMA supplementOct 7, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Allergan

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
2525 Dupont Dr., Irvine, CA, 92612

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records